• 1
    Panyi G. Biophysical and pharmacological aspects of K+ channels in T lymphocytes. Eur Biophys J 2005; 34: 515529.
  • 2
    Cahalan MD,Wulff H,Chandy KG. Molecular properties and physiological roles of ion channels in the immune system. J Clin Immunol 2001; 21: 235252.
  • 3
    Panyi G,Possani LD,Rodríguez de la Vega RC,Gáspár R,Varga Z. K+ channel blockers: Novel tools to inhibit T cell activation leading to specific immunosuppression. Curr Pharm Des 2006; 18: 21992220.
  • 4
    Hu L,Pennington M,Jiang Q,Whartenby KA,Calabresi PA. Characterization of the functional properties of the voltage-gated potassium channel Kv1.3 in human CD4+ T lymphocytes. J Immunol 2007; 179: 45634570.
  • 5
    Beeton C,Wulff H,Barbaria J,Clot-Faybesse O,Pennington M,Bernard D,Cahalan MD,Chandy KG,Béraud E. Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc Natl Acad Sci USA 2001; 98: 1394213947.
  • 6
    Beeton C,Wulff H,Standifer NE,Azam P,Mullen KM,Pennington MW,Kolski-Andreaco A,Wei E,Grino A,Counts DR, et al. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc Natl Acad Sci USA 2006; 103: 1741417419.
  • 7
    Toldi G,Bajnok A,Dobi D,Kaposi A,Kovács L,Vásárhelyi B,Balog A. The effects of Kv1.3 and IKCa1 potassium channel inhibition on calcium influx of human peripheral T lymphocytes in rheumatoid arthritis. Immunobiology. 2012 May 23; [Epub ahead of print] PMID: 22705192.
  • 8
    Kaposi AS,Veress G,Vásárhelyi B,Macardle P,Bailey S,Tulassay T,Treszl A. Cytometry-acquired calcium-flux data analysis in activated lymphocytes. Cytometry A 2008; 73A: 246253.
  • 9
    Kaposi A,Toldi G,Mészáros G,Szalay B,Veress G,Vásárhelyi B. Experimental conditions and mathematical analysis of kinetic measurements using flow cytometry—The FacsKin method. In: Schmid I, editor. Flow Cytometry—Recent Perspectives. Rijeka: Intech; 2012. pp 299324.
  • 10
    Aletaha D,Neogi T,Silman AJ,Funovits J,Felson DT,Bingham COIII,Birnbaum NS,Burmester GR,Bykerk VP,Cohen MD, et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62: 25692581.
  • 11
    Toldi G,Folyovich A,Simon Z,Zsiga K,Kaposi A,Mészáros G,Tulassay T,Vásárhelyi B. Lymphocyte calcium influx kinetics in multiple sclerosis treated without or with interferon beta. J Neuroimmunol 2011; 237: 8086.
  • 12
    Mészáros G,Szalay B,Toldi G,Kaposi A,Vásárhelyi B,Treszl A. Kinetic measurements using flow cytometry: New methods for monitoring intracellular processes. Assay Drug Dev Technol. 2012; 10: 97104.
  • 13
    Bridge PD,Sawilowsky SS. Increasing physicians' awareness of the impact of statistics on research outcomes: Comparative power of the t-test and and Wilcoxon Rank-Sum test in small samples applied research. J Clin Epidemiol 1999; 52: 229235.
  • 14
    Yamamoto J,Adachi Y,Onoue Y,Adachi YS,Okabe Y,Itazawa T,Toyoda M,Seki T,Morohashi M,Matsushima K, et al. Differential expression of the chemokine receptors by the Th1- and Th2-type effector populations within circulating CD4+ T cells. J Leukoc Biol 2000; 68: 568574.
  • 15
    Annunziato F,Cosmi L,Galli G,Beltrame C,Romagnani P,Manetti R,Romagnani S,Maggi E. Assessment of chemokine receptor expression by human Th1 and Th2 cells in vitro and in vivo. J Leukoc Biol 1999; 65: 691699.